Citalopram updated on 07-01-2025

Atrioventricular septal defect

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S7471
R22286		 Anderson, 2020 Atrioventricular septal defect 1st trimester case control unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 3.01 [1.07;8.52] -/-   0/- - -
ref
S6005
R15385		 Furu, 2015 Atrioventricular septal defects 1st trimester population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 1.14 [0.51;2.56] 6/11,193   1,073/2,266,875 1,079 11,193
ref
S7351
R21522		 Wemakor, 2015 Atrioventricular septal defect 1st trimester case control unexposed (general population or NOS) Adjustment: No Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 1.44 [0.09;23.83] C 0/20   290/17,353 290 20
ref
Total 3 studies 1.65 [0.86;3.16] 1,369 11,213
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Anderson, 2020Anderson, 2020 3.01[1.07; 8.52]--37%ROB confusion: seriousROB selection: criticalROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: moderate Furu, 2015Furu, 2015 1.14[0.51; 2.56]1,07911,19358%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Wemakor, 2015Wemakor, 2015 1.44[0.09; 23.83]290205%ROB confusion: criticalROB selection: criticalROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Total (3 studies) I2 = 5% 1.65[0.86; 3.16]1,36911,2130.510.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.14[0.51; 2.55]1,07911,193 -NAFuru, 2015 1 case control studiescase control studies 2.75[1.04; 7.29]290200%NAAnderson, 2020 Wemakor, 2015 2 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.65[0.86; 3.16]1,36911,2135%NAAnderson, 2020 Furu, 2015 Wemakor, 2015 3 Tags Adjustment   - No  - No 1.44[0.09; 23.83]29020 -NAWemakor, 2015 1   - Yes  - Yes 1.75[0.68; 4.50]1,07911,19352%NAAnderson, 2020 Furu, 2015 2 Monotherapy   - substance alone among all Antidep ( ...  - substance alone among all Antidep (SSRI, SNRI, ...) 1.65[0.86; 3.16]1,36911,2135%NAAnderson, 2020 Furu, 2015 Wemakor, 2015 3 All studiesAll studies 1.65[0.86; 3.16]1,36911,2135%NAAnderson, 2020 Furu, 2015 Wemakor, 2015 30.510.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.65[0.86; 3.16]1,36911,2135%NAAnderson, 2020 Furu, 2015 Wemakor, 2015 30.510.01.0